ILK

Across TCGA pan-cancer cohorts, ILK mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ILK data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ILK mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ILK expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, GBM, and LSCC are the cancer types where ILK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.902	0.383	.003	16	view →
GBM	DFS	Quartile	All	0.175	0.514	<.001	10	view →
LSCC	OS	Quartile	II,III,IV	0.742	1.000	.011	8	view →
CCRCC	DFS	Quartile	III,IV	0.700	0.392	.039	3	view →
LUAD	DFS	Median	II,III,IV	0.721	0.937	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ILK–PDAC (DFS)

Open the PDAC breakdown →